# Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

> **NCT01407094** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 296 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Sertraline
- **DRUG:** Placebo
- **DRUG:** BupropionXL

## Key facts

- **NCT ID:** NCT01407094
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-29
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2018-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01407094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01407094, "Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01407094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*